U.S. markets closed

KemPharm, Inc. (KMPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.7600+0.1100 (+2.37%)
At close: 04:00PM EST
4.7000 -0.06 (-1.26%)
After hours: 04:46PM EST

KemPharm, Inc.

1180 Celebration Boulevard
Suite 103
Celebration, FL 34747
United States
321 939 3416

Full Time Employees24

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard W. PascoeExec. Chairman515.43kN/A1964
Dr. Travis C. Mickle Ph.D.Co-Founder, Pres, CEO & Director773.13kN/A1973
Ms. Christal M. M. Mickle M.A.Co-Founder and Sr. VP of Operations & Product Devel.N/AN/A1979
Mr. R. LaDuane Clifton CPACFO, Sec. & Treasurer476.28kN/A1972
Dr. Sven GuentherExec. VP of R&D497.26kN/A1972
Ms. Nichol L. OchsnerVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Timothy J. Sangiovanni CPAVP & Corp. ControllerN/AN/A1984
Dr. Andrew BarrettVP of Scientific AffairsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.

Corporate Governance

KemPharm, Inc.’s ISS Governance QualityScore as of November 28, 2022 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.